Studies
Completed
Thursday, December 14th, 2023 | 10:30 AM and 1:00 PM ET
Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models
Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.
We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.
Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening
Discover the largest commercially available collection of PDX models as well as our novelin vitro models
Utilize our bioinformatics, biomarker analysis, genomics and high content imaging services to advance your preclinical studies
Accelerate your drug development with our biomarker discovery, efficacy testing, DMPK and pharmacology services
Studies
Completed
This data point indicates the total number of studies in Q2 2023 that the CSAT, Customer Effort, and Customer Expectation scores are measured against.
Studies
Completed
Customer
Satisfaction
Also known as CSAT, this metric indicates how satisfied customers are with the complete Crown Bioscience customer experience.
Customer
Satisfaction
Customer
Effort
The Customer Effort Score (CES) is a metric that measures how easy it was to work with Crown Bioscience.
Customer
Effort
Customer
Expectation
This metric indicates the strength of Crown Bioscience in meeting or exceeding customer expectations.
Customer
Expectation
Latest Application Note
Evaluate immunotherapeutics and agents to overcome drug resistance with our NSCLC EGFR exon 19 deletion resources
November 21, 2023
The world of oncology is ever-evolving, and as researchers and scientists, we are perpetually on the front lines searching for innovative solutions against cancer. One promising direction is the exploration of drug combinations. The idea is both simple and profound: what if we could combine two or more drugs, amplifying their effects to produce outcomes greater than their individual impacts? Welcome to the world of drug synergy!
November 17, 2023
Liver cancer remains a major health burden in the U.S. and globally, with incidence rates continuing to rise. Estimates indicate that liver cancer will affect more than 1 million individuals annually in coming years. Hepatocellular carcinoma (HCC), the predominant form that accounts for roughly 90% of primary liver cancer cases, is highly complex and heterogeneous and is often associated with underlying chronic liver disease, such as hepatitis.
October 30, 2023
Selecting the right preclinical model to evaluate a drug candidate’s mechanism of action and efficacy can be challenging given the wide variety of available options and their associated time and cost investments. However, selecting the appropriate model can mean the difference between success and failure for a given drug candidate. 3D in vitro organoids are powerful predictive preclinical models that are ideal for bridging the gap between traditional 2D in vitro cell lines and in vivo studies because they offer a more clinically relevant platform than 2D cell lines prior to transitioning to more costly and time-consuming in vivo validation studies.
October 30, 2023
Dr. Alexander Swarbrick's recent paper on bioRxiv, titled "An experimental comparison of the Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research" delves into a comparative analysis of the DSP and Visium platforms. While both technologies displayed commendable prowess in spatially profiling breast cancer tissues, they shine in distinct areas of application.
© 2023 Crown Bioscience. All Rights Reserved.
© 2023 Crown Bioscience. All Rights Reserved. Privacy Policy